Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia
Public ClinicalTrials.gov record NCT05270863. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Multicenter, Double-Masked, Randomized, Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF Topical Ophthalmic Solution With Emmetropic Phakic and Pseudophakic Presbyopia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
Study identification
- NCT ID
- NCT05270863
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 182 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 45 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 30, 2022 (Actual)
- Primary completion
- Mar 17, 2023 (Actual)
- Completion
- Apr 10, 2023 (Actual)
- Last update posted
- Oct 15, 2024
2022 – 2023
United States locations
- U.S. sites
- 15
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Visus Therapeutics Investigative Site | Glendale | California | 91204 | — |
| Visus Therapeutics Investigative Site | Rancho Cordova | California | 95670 | — |
| Visus Therapeutics Investigative Site | Jacksonville | Florida | 32204 | — |
| Visus Therapeutics Investigative Site | Morrow | Georgia | 30260 | — |
| Visus Therapeutics Investigative Site | Roswell | Georgia | 30076 | — |
| Visus Therapeutics Investigative Site | Shawnee Mission | Kansas | 66204 | — |
| Visus Therapeutics Investigative Site | Kansas City | Missouri | 64133 | — |
| Visus Therapeutics Investigative Site | Kansas City | Missouri | 64154 | — |
| Visus Therapeutics Investigative Site | Pittsburgh | Pennsylvania | 66762 | — |
| Visus Therapeutics Investigative Site | Memphis | Tennessee | 38119 | — |
| Visus Therapeutics Investigative Site | Memphis | Tennessee | 77027 | — |
| Visus Therapeutics Investigative Site | Cedar Park | Texas | 78613 | — |
| Visus Therapeutics Investigative Site | Houston | Texas | 77027 | — |
| Visus Therapeutics Investigative Site | San Antonio | Texas | 78229 | — |
| Visus Therapeutics Investigative Site | Ogden | Utah | 84403 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05270863, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 15, 2024 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05270863 live on ClinicalTrials.gov.